Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

>
1 of 40

David Hung, CEO of Medivation

FierceBiotech caught up with David Hung after the Bay Bio panel Monday morning, at which he touted reasons why the San Francisco Bay Area is particularly suited for life sciences growth. For example, Hung asserted that companies in the industry are broadening their approaches to treating disease, even looking at exploiting the properties of electricity and light to improve outcomes for patients. Here, there is an ingrained "high-tech" level of expertise ideally suited to this type of innovation. Hung also caught us up on the development of enzalutamide (Xtandi), approved last year by the FDA to treat late-stage prostate cancer. The company is now testing the drug for the prechemo market.